Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCO:6704'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -223.8 Med: -174.32 Max: -66.79
Current: -78.7
During the past 6 years, the highest EV-to-EBITDA of Gwo Xi Stem Cell Applied Technology Co was -66.79. The lowest was -223.80. And the median was -174.32.
ROCO:6704's EV-to-EBITDA is ranked worse than 100% of 425
companies
in the Biotechnology industry
Industry Median: 12.66
vs ROCO:6704: -78.70
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Gwo Xi Stem Cell Applied Technology Co (ROCO:6704) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gwo Xi Stem Cell Applied Technology Co's PE Ratio (TTM) for today is calculated as:
Gwo Xi Stem Cell Applied Technology Co's share price for today is NT$21.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gwo Xi Stem Cell Applied Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-1.032.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gwo Xi Stem Cell Applied Technology Co EV-to-EBITDA Chart
Gwo Xi Stem Cell Applied Technology Co Annual Data
ROCO:6704 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Gwo Xi Stem Cell Applied Technology Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gwo Xi Stem Cell Applied Technology Co EV-to-EBITDA vs Biotechnology Industry
Gwo Xi Stem Cell Applied Technology Co's current Enterprise Value is NT$2,219.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gwo Xi Stem Cell Applied Technology Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-28.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gwo Xi Stem Cell Applied Technology Co (ROCO:6704) has a EV-to-EBITDA of -78.70 as of Sep. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gwo Xi Stem Cell Applied Technology Co. According to the industry distribution chart, Gwo Xi Stem Cell Applied Technology Co ranks #999999 out of 425 companies in the Biotechnology industry.
Is Gwo Xi Stem Cell Applied Technology Co's EV-to-EBITDA too high?
Gwo Xi Stem Cell Applied Technology Co's current EV-to-EBITDA is -78.70. Based on the distribution chart, Gwo Xi Stem Cell Applied Technology Co ranks #999999 out of 425 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gwo Xi Stem Cell Applied Technology Co has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gwo Xi Stem Cell Applied Technology Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gwo Xi Stem Cell Applied Technology Co ranks #999999 out of 425 companies for EV-to-EBITDA. This places Gwo Xi Stem Cell Applied Technology Co in the lower half of its industry. The industry median EV-to-EBITDA is 12.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.66, based on 425 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gwo Xi Stem Cell Applied Technology Co. For the Biotechnology industry, the median EV-to-EBITDA is 12.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gwo Xi Stem Cell Applied Technology Co's current EV-to-EBITDA is -78.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gwo Xi Stem Cell Applied Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Gwo Xi Stem Cell Applied Technology Co (ROCO:6704) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$25.50, compared to a current price of NT$21.00 — trading 17.6% below its estimated fair value. The current EV-to-EBITDA is -78.70. Gwo Xi Stem Cell Applied Technology Co's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Gwo Xi Stem Cell Applied Technology Co (ROCO:6704), the current EV-to-EBITDA is -78.70 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gwo Xi Stem Cell Applied Technology Co (ROCO:6704) Overvalued in 2026?
Based on GuruFocus' analysis, Gwo Xi Stem Cell Applied Technology Co stock appears to be undervalued.
The current stock price of NT$21.00 is trading 17.6% below its estimated GF Value™ of NT$25.50.
GuruFocus considers Gwo Xi Stem Cell Applied Technology Co to be Modestly Undervalued.
Key valuation signals for ROCO:6704:
EV-to-EBITDA: -78.70
GF Value™: NT$25.50 vs. price of NT$21.00 (17.6% below fair value)
No single metric tells the full story. See the ROCO:6704 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gwo Xi Stem Cell Applied Technology Co is committed to developing stem cell medicines that have the potential to help patients with unmet medical needs.
54GF Score
Get the complete analysis for ROCO:6704
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6704 has been successfully added to your 
